Back

Country specific mutational profile of SARS-CoV-2 in pre- and post-international travel ban: Effect on vaccine efficacy

Laha, S.; Chatterjee, R.

2021-02-11 infectious diseases
10.1101/2021.02.08.21251359
Show abstract

In order to curb the rapid transmission of SARS-CoV-2, nation-wide lockdowns were implemented as a preliminary measure. Since most countries enforced travel-bans during end of March 2020, the country-specific patterns should be discernible in the subsequent months. We identified frequently mutated non-synonymous mutations in 2,15,000 SARS-CoV-2 sequences during pre and post-travel-ban periods in 35 countries. We further investigated the mutational profile on a bi-monthly basis and traced the progress over the time. Several new mutations have emerged post-travel-ban and on the rise in specific countries, chief among them being A222V and S477N in Spike, and A220V in Nucleocapsid protein. Consequently, we examined the Spike protein epitopes to inspect whether any of these country-specific mutations overlapped with these epitopes. Several mutations were found to be contained within one or more epitopes, including the highly mutated residues of Spike protein, advocating the requirement of active monitoring of vaccine efficacies in respective countries.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Journal of Medical Virology
based on 95 papers
Top 0.1%
13.5%
2
Emerging Microbes & Infections
based on 20 papers
Top 0.1%
7.7%
3
PLOS ONE
based on 1737 papers
Top 70%
4.8%
4
Viruses
based on 79 papers
Top 0.5%
4.8%
5
Scientific Reports
based on 701 papers
Top 42%
4.6%
6
Vaccines
based on 131 papers
Top 1%
4.6%
7
Emerging Infectious Diseases
based on 84 papers
Top 3%
3.0%
8
Frontiers in Medicine
based on 99 papers
Top 7%
2.5%
9
Frontiers in Microbiology
based on 36 papers
Top 0.7%
2.5%
10
Nature Communications
based on 483 papers
Top 25%
2.5%
50% of probability mass above
11
International Journal of Infectious Diseases
based on 115 papers
Top 6%
2.5%
12
Journal of Infection
based on 64 papers
Top 2%
2.4%
13
Clinical Infectious Diseases
based on 219 papers
Top 12%
2.4%
14
Journal of Clinical Virology
based on 54 papers
Top 2%
1.6%
15
Eurosurveillance
based on 77 papers
Top 4%
1.6%
16
Frontiers in Public Health
based on 135 papers
Top 20%
1.3%
17
Infection, Genetics and Evolution
based on 14 papers
Top 0.7%
1.3%
18
Journal of Clinical Microbiology
based on 77 papers
Top 4%
1.2%
19
Frontiers in Immunology
based on 140 papers
Top 6%
1.2%
20
PLOS Pathogens
based on 35 papers
Top 2%
1.2%
21
Journal of Infection and Chemotherapy
based on 15 papers
Top 0.4%
1.2%
22
The Lancet Infectious Diseases
based on 57 papers
Top 6%
1.2%
23
Open Forum Infectious Diseases
based on 124 papers
Top 10%
0.8%
24
Nature Medicine
based on 88 papers
Top 15%
0.8%
25
iScience
based on 74 papers
Top 7%
0.8%
26
mBio
based on 34 papers
Top 3%
0.8%
27
BMC Infectious Diseases
based on 110 papers
Top 17%
0.8%
28
Virus Evolution
based on 26 papers
Top 1%
0.7%
29
Clinical Microbiology and Infection
based on 54 papers
Top 6%
0.7%
30
Journal of Infection and Public Health
based on 15 papers
Top 2%
0.7%